Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
FOXO4-DRI is a large peptide (~5382 Da, 48 amino acids) with a critical structural modification: the D-Retro-Inverso (DRI) design uses D-amino acids in reversed sequence to confer protease resistance while maintaining the 3D spatial arrangement needed for target binding
BPC-157 is not FDA-approved and is used off-label based on preclinical evidence and clinical experience
BPC-157 may be utilized alongside other therapies such as: Stem Cell Therapy Stem cell-based therapies are being studied for their potential role in tissue support and recovery across multiple medical applications
the only controlled human clinical data covers dermal wound healing
Lurie J, Tomkins-Lane C
US$ 28.09
US$ 27.11
US$ 24.86
